[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616432":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":59,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":20,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":20,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":87,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Western University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"¹⁹F (perfluoropropane) MRI","EXPERIMENTAL","Participants will undergo pulmonary function tests, ¹⁹F (perfluoropropane) MRI at the visit.",[13],"Device: 19F(perfluoropropane) MRI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","19F(perfluoropropane) MRI","19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.",[9],null,[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Hana Serajeddini, MD, FRCPC","CONTACT","(519) 646-6100","66288","hana.serajeddini@lhsc.on.ca",{"name":29,"role":24,"phone":20,"phoneExt":20,"email":30},"Tommy Li, Msc","zli3569@uwo.ca",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"St Joseph's Healthcare London","London","Ontario","N6A 4V2","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-81.23304,42.98339,{"lat":43,"lon":42},[46,48,50,53,56,58],{"name":23,"role":24,"phone":47,"phoneExt":26,"email":27},"519) 646-6100",{"name":49,"role":24,"phone":20,"phoneExt":20,"email":30},"Tommy Li",{"name":51,"role":52,"phone":20,"phoneExt":20,"email":20},"Alexei Ouriadov, PhD","PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":20,"phoneExt":20,"email":20},"Anurag Bhalla, MD, FRCPC","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":20,"phoneExt":20,"email":20},"Grace Parraga, PhD",{"name":23,"role":52,"phone":20,"phoneExt":20,"email":20},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Alexei Ouriadov","PhD, professor, scientist",[64],{"name":65,"class":6},"St. Joseph's Health Care London","100616432","f-perfluoropropane-mri-100616432",false,"NCT07305532","¹⁹F (Perfluoropropane) MRI","HARDWARE AND SOFTWARE DEVELOPMENT FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED INERT FLOURINATED GAS","Inclusion Criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.\n2. Provision of written, informed consent prior to any study specific procedures.\n3. Males and females aged 18 to 85 years.\n4. Participant must be able to perform a breath-hold for 16s.\n5. Participant has a BMI between 18 and 40\n6. Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)\n7. Participants are judged to be in stable health on the basis of medical history\n\nExclusion Criteria:\n\nParticipants fulfilling any of the following criteria are not eligible for inclusion in this study:\n\n1. Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist).\n2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.\n3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.\n4. Participant is unable to perform spirometry maneuvers.\n5. Participant is unable to perform MRI and CT breath-hold maneuvers.\n6. Participant has a history of chronic or acute respiratory disease\n7. FEV1 \\\u003C70%\n8. Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)\n9. Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine",true,"ALL","18 Years","85 Years",{"count":78,"type":79},200,"ESTIMATED","INTERVENTIONAL",[82],"NA","Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.",[85],"Healthy Volunteers - Male and Female",[17],"NOT_YET_RECRUITING","2026-04-16",{"date":90,"type":91},"2026-04-22","ACTUAL",{"date":93,"type":79},"2026-05-20",{"date":95,"type":79},"2030-12-30",{"name":61,"class":6},1]